We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

By LabMedica International staff writers
Posted on 23 May 2024

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. More...

These conditions are caused by the clumping together of the smallest building blocks in the body that disrupts vital functions. Within our cells, numerous interactions and exchanges among proteins and other molecules occur naturally, allowing our bodies to function properly. However, errors in these processes can lead to protein clumps that impair functionality, underpinning a variety of neurodegenerative disorders affecting the brain, including Alzheimer's and dementia. Understanding why this clumping occurs and how to treat it has remained elusive, largely due to a lack of adequate tools to study these phenomena. Researchers have now introduced a groundbreaking tool that can find these tiny protein clumps in microscopy images and lead to improved understanding and treatments of diseases like cancer, Alzheimer's, and Parkinson's.

Scientists at the University of Copenhagen (Copenhagen, Denmark) have developed a machine learning algorithm capable of observing protein clumping in real time under a microscope. This algorithm is capable of automatically identifying and monitoring the critical characteristics of the clumped-up building blocks responsible for Alzheimer's and other neurodegenerative diseases—a task previously unachievable. It can detect protein clumps as small as a billionth of a meter in microscopy images and categorize these clumps by their shape and size while tracking their development. The physical appearance of these clumps significantly influences their function and behavior within the body, whether detrimental or beneficial.

Going forward, this algorithm will simplify the process of discovering why clumps form, thereby aiding the development of new medications and therapies to fight these debilitating disorders. The researchers are actively using this tool in experiments with insulin molecules, which, when clumped, lose their ability to regulate blood sugar effectively. The tool allows for the observation of how these clumps change when exposed to various compounds, paving the way to potentially halt or alter them into less harmful or more stable forms. The team is optimistic about the tool's potential to facilitate drug development once these tiny building blocks are precisely identified. They anticipate that their efforts will initiate the gathering of more comprehensive knowledge regarding the shapes and functions of proteins and molecules. The algorithm is accessible as open-source software on the internet for use by scientific researchers and others interested in exploring the clumping of proteins and other molecules.

"In just minutes, our algorithm solves a challenge that would take researchers several weeks. That it will now be easier to study microscopic images of clumping proteins will hopefully contribute to our knowledge, and in the long term, lead to new therapies for neurodegenerative brain disorders," said PhD Jacob Kæstel-Hansen, who led the research team behind the algorithm.

Related Links:
University of Copenhagen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.